Tags: Chemical Compound, Chemical Substance.

SB-431542 is a drug candidate developed by GlaxoSmithKline (GSK) as an inhibitor of the activin receptor-like kinase (ALK) receptors ALK5 ALK4 and ALK7. It also suppressed the TGF-beta-induced proliferation of osteosarcoma cells in humans.

SB431542.png

Loading...

This page contains content from the copyrighted Wikipedia article "SB-431542"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.